DEPARTMENT OF THE ARMYUS ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY
820 CHANDLER STREETFORT DETRICK MD 21702-5014

2 February 2021
Advanced Technology International (ATI)ATTN: (b) (6), Contracts Manager
315 Sigma Drive
Summerville, SC 29486
Dear (b) (6):SUBJECT: Revised Project Approval Letter (PAL) for 20-12-COVID19-Diagnostics-001 for“Modified PPD Test for Detection and Scalable Monitoring of the Covid-19 Antibody andBeyond” to Diomics Corporation, PAL Version 2
REF: Request for Project Approval from ATI dated 18 August 2020 for 20-12-COVID19Diagnostics-001 under OTA W81XWH-15-9-0001
EGS#: MT20012.001
The purpose of this revised PAL is to:Reflect a 4-month extension at no additional cost to the Government and incorporate arevised SOW and MPS as an enclosure.
In support of the U.S. Army Medical Research and Development Command (USAMRDC), ATI,
on behalf of the Medical Technology Enterprise Consortium (MTEC) issued Request for Project
Proposal (RPP) number MTEC-20-12-COVID19-Diagnostics on 1 May 2020. Both current andprospective members of the MTEC submitted Enhanced White Papers in response to this RPP, inaccordance with the terms of the RPP. (b) (4)Subsequently, the Government evaluated those Enhanced
White Papers that passed the Government’s initial screening process in accordance with thestated evaluation criteria. (b) (4).
Based upon the evaluation of Diomics Corporation’s proposal (20-12-COVID19-Diagnostics001) entitled, “Modified PPD Test for Detection and Scalable Monitoring of the Covid-19
Antibody and Beyond,” and ATI’s request for PAL (which includes the Statement of Work(SOW), inclusive of an acceptable milestone schedule), the Government issued an initial Project
Approval Letter (PAL), dated 27 August 2020, which authorized ATI to issue a Research ProjectAward (RPA) to Diomics Corporation for the subject initiative. As stated in the aforementionedPAL, a separate Other Transaction Agreement (OTA) Task Order modification, W81XWH-20-90015-P00001 was issued which fully funded Diomics Corporation’s awarded costs.
The Sponsor Office Technical Representative (SOTR) for this RPA is (b) (6)SUBJECT: Revised PAL for 20-12-COVID19-Diagnostics-001 for “Modified PPD Test for
Detection and Scalable Monitoring of the Covid-19 Antibody and Beyond” to Diomics
Corporation, PAL Version 2The period of performance (POP) of the Research Project Award has been extended from 8months to approximately 12 months as a result of this Revised PAL for a new end date of 9 June
2021. Note, however, that the POP within the OTA Task Order, W81XWH-20-9-0015, includes
additional time to account for the final negotiations between ATI and all performers included
under the “Wearable Diagnostic for Detection of COVID-19 Infection” Task Order. Thisadditional time is intended to align the end dates for the Task Order and RPAs.
Special Considerations
a. The Government has not identified any national security restrictions that apply to thisRPA.
b. The following special research considerations are applicable to this award: use of humansubjects and animal subjects. Approval from the MRDC Human Research Protections
Office (HRPO) must be obtained prior to commencement of the tasks involving humansubjects. Additionally, approval from the MRDC Animal Care and Use Review Office(ACURO) must be obtained prior to commencement of the tasks involving animalsubjects.
Data Rights
As stated in Diomics Corporation’s proposal entitled, “Modified PPD Test for Detection andScalable Monitoring of the Covid-19 Antibody and Beyond,” all under this prototype project will
be delivered to the Government with unlimited data rights.
Pre-Award Cost Authorization
The Agreements Officer has authorized pre-award costs for the RPA to Diomics Corporation. As
the Pre-Award Cost Authorization (PACA) letter was fully executed between ATI and Diomics
Corporation on 13 July 2020, the Government agrees to pay allowable costs accrued in theperformance of this RPA starting on this date (13 July 2020) through the end of the period ofperformance in an amount not to exceed $190,000.00. Additionally, the Agreements Officerauthorized the allowance of costs incurred by Diomics Corporation as Cost Share (AnticipatedNon-Federal Contribution) starting on this date (13 July 2020).
The total authorized value has been determined fair and reasonable and this proposal has been
selected in accordance with the RPP evaluation criteria. The Agreements Officer documented
the appropriate use of Section 815 prototype OTA authority at the time of award. The total
approved cost to the Government for this effort is Not-to-Exceed (NTE) $2,113,146.00 (note thatthe “Total Program Cost” value listed in the table below of (b) (4)is inclusive of the
Anticipated Non-Federal Contribution).

2